212 filings
Page 2 of 11
8-K
sk7pgrh3
1 Sep 22
GeoVax Announces Addition to its Board of Directors
4:49pm
8-K
15tgwb18f
1 Sep 22
Submission of Matters to a Vote of Security Holders
4:48pm
8-K
14rns
4 Aug 22
GeoVax Reports 2022 Second Quarter Financial Results
4:06pm
8-K
grjncb
27 May 22
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules
4:48pm
8-K
legvcnf s6wl8a5u6
2 May 22
GeoVax Reports 2022 First Quarter Financial Results
7:30am
8-K
id9vkin2jur a4m
10 Mar 22
GeoVax Reports 2021 Year-End Financial Results
5:02pm
8-K
rl9kyqa
20 Jan 22
GeoVax Announces $10 Million Private Placement
4:30pm
8-K
or7ynhqt76 68famcws
4 Jan 22
GeoVax Issues Shareholder Update Letter
5:14pm
8-K
az57uo8v40q
15 Dec 21
GeoVax Announces Initiation of Phase 2 Clinical Trial
4:11pm
8-K
72v 3yum6
12 Nov 21
GeoVax Reports 2021 Third Quarter Financial Results
1:37pm
8-K
ztuyvpb7
10 Nov 21
GeoVax and City of Hope Announce Agreement to
4:41pm
8-K
kitx5s2tb2 1k5ko
30 Sep 21
GeoVax Gedeptin License Announcement Call
4:05pm
8-K
9xo h6jvpa9o38w6
29 Sep 21
Entry into a Material Definitive Agreement
4:15pm
8-K
e8odw n86
20 Aug 21
GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly
9:00am
8-K
mlyw90e
11 Aug 21
GeoVax Reports 2021 Second Quarter Financial Results
4:30pm
8-K
3ql n74cg8
7 May 21
GeoVax Reports 2021 First Quarter Financial Results
1:05pm
8-K
ng2bh 4w2c3t2r
23 Mar 21
GeoVax Reports 2020 Year-End Financial Results
4:35pm
8-K
o8h15aj svn9
11 Feb 21
GeoVax Announces Closing of $10.3 Million Bought Deal Offering
2:35pm
8-K
8ucdl9rjagofi7
11 Feb 21
GeoVax Announces Pricing of $9.0 Million Bought Deal Offering
9:21am
8-K
jkonw
30 Nov 20
GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development
5:18pm